Cresco Labs Files Proxy Materials for October Shareholder Meeting as It Advances U.S. Exchange Listing Plans
Cresco Labs Inc. has filed its Management Information Circular and related proxy materials ahead of its annual general and special meeting of shareholders, scheduled for October 30, 2026. The company is seeking shareholder approval for a series of corporate restructuring measures that are intended to prepare Cresco Labs for a potential listing on a senior U.S. stock exchange.
The proposed transactions would involve the creation of a new parent company, referred to as TopCo, followed by a potential redomicile of that entity from British Columbia to Delaware. Shareholders will also be asked to approve an amendment to the sunset provisions governing Cresco Labs’ multiple voting shares, or MVS.
The measures represent a proposed restructuring of Cresco Labs’ corporate and capital structure as the company evaluates access to U.S. capital markets. According to the company, the proposed changes are intended to simplify the organization, reduce administrative complexity and create a structure more suited to a potential U.S. exchange listing.
“The proposals we are putting before shareholders are designed to position Cresco Labs for listing on a senior U.S. exchange,” said Charles Bachtell, CEO of Cresco Labs. “Taken together, they streamline our corporate and capital structure while lowering administrative cost and complexity.”
Three Special Resolutions at the Center of the Meeting
Shareholders will be asked to consider three special resolutions at the October meeting. The first concerns a proposed share exchange that would establish TopCo as the new publicly listed parent company. The second relates to a potential redomicile of TopCo from British Columbia to Delaware. The third would extend the sunset date applicable to the company’s MVS from one year to three years following a U.S. listing.
Cresco Labs said the proposed measures are part of its broader preparations for a possible senior U.S. exchange listing. Each resolution would address a different element of the company’s existing corporate structure.
The proposals are subject to shareholder approval and other applicable conditions. The company has emphasized that the descriptions contained in its announcement are summaries and that shareholders should review the complete Management Information Circular and other meeting materials before voting.
Share Exchange Would Establish New TopCo Parent
Under the first special resolution, Cresco Labs is proposing a share exchange that would create TopCo as the company’s new publicly listed parent entity.
The proposed transaction is intended to simplify Cresco Labs’ capital structure ahead of a potential move to a senior U.S. exchange. As part of the Share Exchange, securities currently held by Cresco Labs shareholders would be exchanged for corresponding securities of TopCo.
According to the company, the exchange would apply across all classes of Cresco Labs shares. The stated objective is to ensure that shareholders’ relative voting and economic interests remain unchanged through the restructuring.
The Board of Directors would also have discretion to implement a reverse share split if one becomes necessary to satisfy the listing requirements of a senior U.S. stock exchange.
A reverse share split generally reduces the number of outstanding shares while proportionally increasing the share price, without changing the overall economic value of a shareholder’s position solely as a result of the split. The company has indicated that this authority would be used only if required in connection with exchange-listing requirements.
The proposed Share Exchange would therefore establish the corporate framework that Cresco Labs believes could facilitate a future U.S. listing while reducing administrative requirements associated with its current structure.
Delaware Redomicile Proposed Following Share Exchange
The second special resolution concerns the proposed redomicile of TopCo from British Columbia to Delaware.
If approved, the transaction would change the legal domicile of the new parent company and involve corresponding changes to its share capitalization. The proposed structure would also include the adoption of a new long-term equity incentive plan intended for a U.S.-domiciled issuer.
The Board would have discretion to implement the Redomicile after completion of the Share Exchange. Under the proposal, the Redomicile could take place at any time on or before December 31, 2027.
Cresco Labs said establishing TopCo in Delaware would create a corporate structure that is more familiar to U.S. investors while aligning the company’s domicile with its operational jurisdiction. The company also expects the structure could support access to U.S. capital markets if it proceeds with a senior U.S. exchange listing.
Delaware is widely used as a corporate domicile by U.S. companies, particularly because of its established corporate legal framework. For Cresco Labs, the proposed move would form part of a broader effort to establish a corporate structure suitable for a potential U.S. public-market listing.
However, approval of the Redomicile would not by itself constitute a completed U.S. exchange listing. The company’s proposed transactions and any future listing would remain subject to applicable requirements and approvals.
Proposed Extension of Multiple Voting Share Sunset
The third special resolution focuses on Cresco Labs’ multiple voting shares.
The company is asking shareholders to approve an amendment that would extend the sunset period for the MVS from the first anniversary of a U.S. listing to the third anniversary.
Cresco Labs said the proposed extension is intended to provide continuity as the company works through the proposed corporate restructuring, completes the potential Redomicile and pursues a U.S. listing.
Under the proposal, the MVS would automatically convert following the applicable sunset period after a U.S. listing. The company has described the amendment as a limited extension designed to provide additional time during the transition to a U.S.-domiciled and potentially U.S.-listed structure.
The MVS proposal is therefore connected to the broader restructuring rather than representing a standalone change to the company’s capital structure.
Annual Business Also on Meeting Agenda
In addition to the three special resolutions, Cresco Labs shareholders will vote on the regular business associated with the company’s annual general meeting.
Shareholders will receive Cresco Labs’ financial statements for the fiscal years ended December 31, 2025 and December 31, 2024, along with the accompanying information.
The annual meeting agenda also includes a proposal to set the number of directors at seven and the election of directors. Shareholders will further vote on the reappointment of Baker Tilly US, LLP as the company’s independent auditor.
The Cresco Labs Board has unanimously recommended that shareholders vote in favor of each resolution being presented at the Meeting.
Because the proposals involve changes to the company’s corporate structure, capital arrangements and governance framework, the company has encouraged shareholders to review the full Circular and related materials rather than relying solely on the summary provided in the announcement.
October 30 Virtual Shareholder Meeting
Cresco Labs’ Annual General and Special Meeting of Shareholders is scheduled for 12:00 p.m. Central Daylight Time on Friday, October 30, 2026.
The Meeting will be conducted through a live audio webcast, allowing shareholders to participate remotely.
Shareholders who were registered holders as of the close of business on September 15, 2026, are entitled to receive notice of and vote at the Meeting.
For shareholders voting by proxy, completed proxies must be received by 12:00 p.m. Central Daylight Time on Wednesday, October 28, 2026. The same deadline applies two business days before any adjourned or postponed Meeting, subject to the applicable requirements.
Beneficial shareholders who own Cresco Labs securities through a broker, financial institution or another intermediary are subject to the voting procedures established by that intermediary. Such shareholders may face an earlier voting deadline and have been advised to follow the instructions supplied by their intermediary.
Shareholders requiring assistance with the Meeting or the voting process can contact Laurel Hill Advisory Group. The company has provided a toll-free telephone and text number within North America at 1-877-452-7184, a telephone number outside North America at 1-416-304-0211, and the email address assistance@laurelhill.com.
Meeting Documents Available Through Regulatory Filings
The Management Information Circular and related meeting materials are available through Cresco Labs’ regulatory filings and corporate website.
Shareholders can access the documents through the company’s profile on SEDAR+, the Canadian securities filing system, as well as through the company’s filings on EDGAR. The materials are also available through Cresco Labs’ corporate website.
The company has advised shareholders that the descriptions in its announcement do not constitute a complete explanation of the proposed transactions. The full Circular contains additional information about the resolutions, corporate governance arrangements, shareholder rights, voting procedures and other matters relevant to the Meeting.
Shareholders are therefore encouraged to read the Circular and all related documents carefully before making decisions regarding the proposed resolutions.
Regulatory and Solicitation Disclosures
Cresco Labs has also clarified that its announcement does not constitute an offer to sell, or a solicitation of an offer to buy or exchange, securities. It also does not constitute a solicitation of votes or approvals in any jurisdiction beyond the proxy solicitation associated with the Meeting.
The company stated that no offering of securities will be made except through documentation that satisfies applicable Canadian and U.S. securities laws. Any future securities transaction or exchange would remain subject to the relevant legal and regulatory requirements.
Cresco Labs also disclosed that the company, its directors, executive officers and certain members of management and employees may be considered participants in the solicitation of shareholder proxies for matters to be addressed at the Meeting.
Information regarding these individuals, including their direct or indirect interests in the matters being considered, is contained in the Management Information Circular and the company’s other regulatory filings.
Potential U.S. Market Structure Remains the Focus
The October 2026 shareholder meeting comes as Cresco Labs evaluates a corporate structure intended to support a potential listing on a senior U.S. exchange.
The proposed sequence would begin with the Share Exchange and establishment of TopCo, followed by a potential Delaware Redomicile. The company is also seeking additional time under its MVS sunset provisions to maintain continuity during the transition.
Taken together, the proposals would represent a significant restructuring of Cresco Labs’ corporate framework while the company seeks to position itself for potential participation in U.S. capital markets.
The proposed transactions remain subject to shareholder approval and applicable regulatory and legal requirements. The October 30 Meeting will provide shareholders with the opportunity to consider the three special resolutions alongside the company’s regular annual business, including director elections, auditor reappointment and receipt of financial statements.
For Cresco Labs, the proposed restructuring represents the next stage in its stated efforts to simplify its corporate structure and prepare for a potential senior U.S. exchange listing. The outcome of the shareholder vote and any subsequent implementation steps will determine how and when the proposed TopCo structure, Delaware Redomicile and revised MVS sunset provisions are put into effect.
About Cresco Labs Inc.
Cresco Labs’ mission is to normalize and professionalize the medical marijuana industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi, on a national level.
The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust medical marijuana industry possible.